Our Story

Our Story

Jawaab was born from a simple but powerful idea: what if getting a disease state and pharma drug question answered felt as natural as asking a trusted colleague in the hallway?

In today’s reality, that kind of HCP access is rare. Reps are blocked. HCPs are busier than ever. And even when they do ask questions about new drugs, dosing, or treatment comparisons, the options are limited: websites, platforms are either slow to respond, they are self-service portals that are hard to navigate, or sources that are not always compliant or clinically credible. The result? Questions go unanswered, or worse, answered inaccurately.

At ValueDo, we have spent over a decade helping 20+ global pharma companies across 25+ countries navigate these engagement gaps. Again and again, we saw one thing: HCPs still want prompt, accurate, credible answers when they need them. Pharma still wants impact. But the channels are somewhat broken.

At ValueDo, we have spent over a decade helping 20+ global pharma companies across 25+ countries navigate these engagement gaps. Again and again, we saw one thing: HCPs still want prompt, accurate, credible answers when they need them. Pharma still wants impact. But the channels are somewhat broken.

This is why JAWAAB, an AI-powered, compliant, human-like platform that acts like your 24/7 digital rep or MSL that is an encyclopedia of available topics. Trained on MLR-approved content, grounded in clinical accuracy, and co-designed with real doctors, pharma, and tech experts, Jawaab gives HCPs precisely this.

Jawaab is setting a new benchmark for digital engagement. Because when HCPs ask, pharma should be ready to answer.

Jawaab is setting a new benchmark for digital engagement. Because when HCPs ask, pharma should
be ready to answer.

  • GSK

  • ETHICON

  • SANOFI

  • Daiichi-Sankyo

  • NOVARTIS

  • AstraZeneca

  • GSK

  • ETHICON

  • SANOFI

  • Daiichi-Sankyo

  • NOVARTIS

  • AstraZeneca

  • GSK

  • ETHICON

  • SANOFI

  • Daiichi-Sankyo

  • NOVARTIS

  • AstraZeneca

A ValueDo Product

Jawaab © 2025. All Rights Reserved. U.S. Utility Patent Pending.

A ValueDo Product

Jawaab © 2025. All Rights Reserved.U.S. Utility Patent Pending.

A ValueDo Product

Jawaab © 2025. All Rights Reserved.
U.S. Utility Patent Pending.